Recent News

lung,cancer,blue,mass

Best of 2024: Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease

Jack Cush, MD

A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).

Read Article
pills-384846_640%20%281%29.jpg

Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis

Jack Cush, MD

A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate analgesic prescription annual prevalence in patients with RA, PsA and axSpA and found that analgesic prescribing declined over time but remained common

Read Article
Palliative Care in Rheumatology Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/fqx8wGLTqI https://t.co/5mwJx3ZN6u

Links:

Dr. John Cush @RheumNow (  View Tweet)
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush @RheumNow (  View Tweet)
Biomarker Study of 171 synovial fluid samples (54 primary OA, 57 RA, 30 Crystal,30 septic arthritis) examined the cartilage oligomeric matrix protein (COMP) to IL-8 ratio and found it can differentiate primary OA and inflamm arthritis w/ sensitivity 87% and specificity 89%… https://t.co/UH77DFgAlJ https://t.co/MfXQcl0BhW
Dr. John Cush @RheumNow (  View Tweet)
Best of 2024: Prescription Painkiller Misuse in Chronic Pain Patients https://t.co/AyccRCuAHh https://t.co/RYuvDwHANo

Links:

Dr. John Cush @RheumNow (  View Tweet)
Abuse of the Safety-Net 340B Drug Programs Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
Dr. John Cush @RheumNow (  View Tweet)
eyes

Best of 2024: Diagnosing Seronegative Sjogren's Disease

Jack Cush, MD

Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy.

Read Article
Seo RNL

Best of 2024: Vasculitis Pearls

Richard Conway, MBBChBAO, PhD

Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you

Read Article
ICYMI: JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush @RheumNow (  View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz

Links:

Dr. John Cush @RheumNow (  View Tweet)
Biosimilars Do Impact Biologic Drug Costs Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars… https://t.co/UoVMc3lSxR https://t.co/A8Sl9bzvla
Dr. John Cush @RheumNow (  View Tweet)
Natl Center for health statistics 11/24 report shows in 2023, 24% of adults had chronic pain (8.5% that limited life/work=high-impact chronic pain). Chronic pain and high-impact chronic pain both increased with age & decreasing urbanization. https://t.co/tMmgHVWnCf https://t.co/O3P4Vrmkei

Links:

Dr. John Cush @RheumNow (  View Tweet)
Rheumatic findings in sarcoidosis are found in 10–40% of pts and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, https://t.co/WsfmKUS2n5 https://t.co/3j8OHgw7AS

Links:

Dr. John Cush @RheumNow (  View Tweet)
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/OC7jNHdFMn https://t.co/cCCO70Xzoh

Links:

Dr. John Cush @RheumNow (  View Tweet)
ICYMI: Sex related differences in PsA Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and… https://t.co/60vdbWLltB https://t.co/nY1CuJhKMb
Dr. John Cush @RheumNow (  View Tweet)
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/pqfmFGT0D6 https://t.co/zo0APuAcQS
Dr. John Cush @RheumNow (  View Tweet)
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS
Dr. John Cush @RheumNow (  View Tweet)
U.S. Preventive Services Task Force (USPSTF) has recommended AGAINST use of vitamin D +/- Ca for the primary prevention of fractures (or falls) in postmenopausal women/men > 60 years of age. or older.https://t.co/1bUBqTVaX0 https://t.co/AXWxduVkOT

Links:

Dr. John Cush @RheumNow (  View Tweet)
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease: ➡️ A. Ogdie: Preventing PsA ➡️ A. Kavanaugh: Biologic Therapies ➡️ K. Gordon: Head-to-Head Studies Register now! https://t.co/BTLmc8HSKY https://t.co/KVsLF3yOZx

Links:

Dr. John Cush @RheumNow (  View Tweet)

From the blog

rheumthought

Overlap Syndrome with ILD

Jack Cush, MD
Cush RheumThought ILD

How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?

Read Article

Podcasts

  • Bah Humbug Vitamin D (12.20.2024)
  • 54K Peptic Ulcers Annually (12.13.2024)
  • Don’t Buy Guitars (12.6.2024)
  • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
Ask Cush Anything

Submit your Rheumatology question or case here

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×